Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4765-4775

  Ikeda, Keiro ^a   Wakimoto, Hiroaki ^a   Ichikawa, Tomotsugu ^a   Jhung, Sarah ^a   Hochberg, Fred H ^a   Louis, David N ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COMPLEMENT; CYCLOPHOSPHAMIDE; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; FEMALE; GLIOMA; HERPES SIMPLEX VIRUS; HUMORAL IMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; SOUTHERN BLOTTING; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BRAIN; BRAIN NEOPLASMS; COBRA VENOMS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOMA; HERPES SIMPLEX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUTATION; RATS; RATS, NUDE; SIMPLEXVIRUS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 0033997183     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4765-4775.2000     Document Type: Article

References (74)

1. Aghi, M., T. C. Chou, K. Suling, X. O. Breakefield, and E. A. Chiocca. 1999. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/ herpes simplex virus thymidine kinase gene therapies. Cancer Res. 59:3861-3865.
2. Anderson, S. C., D. E. Johnson, M. P. Harris, H. Engler, W. Hancock, W. M. Huang, K. N. Wills, R. J. Gregory, S. Sutjipto, S. F. Wen, S. Lofgren, H. M. Shepard, and D. C. Maneval. 1998. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin. Cancer Res. 4:1649-1659.
3. Ash, R. J. 1986. Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells. Virology 155:584-592.
4. Ballow, M., and C. G. Cochrane. 1969. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J. Immunol. 103:944-952.
5. Barnard, R. O., and J. F. Geddes. 1987. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer 60:1519-1531.
6. Barnett, F. H., N. G. Rainov, K. Ikeda, D. E. Schuback, P. Elliott, C. M. Kramm, M. Chase, N. H. Qureshi, G. T. Harsh, E. A. Chiocca, and X. O. Breakefield. 1999. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 6:14-20.
7. Bartus, R. T., P. J. Elliott, R. L. Dean, N. J. Hayward, T. L. Nagle, M. R. Huff, P. A. Snodgrass, and D. G. Blunt. 1996. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142:14-28.
8. Berger, M. S., M. Prados, J. C. VanGilder, et al. 1997. Gene therapy for the treatment of recurrent glioblastoma multiforme with in vivo transduction using the herpes simplex-thymidine kinase gene/ganciclovir system. J. Neurosurg. 1997:378A.
9. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
10. Boviatsis, E. J., M. Chase, M. X. Wei, T. Tamiya, R. K. Hurford, Jr., N. W. Kowall, R. I. Tepper, X. O. Breakefield, and E. A. Chiocca. 1994. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther. 5:183-191.
11. Boviatsis, E. J., J. S. Park, M. Sena-Esteves, C. M. Kramm, M. Chase, J. T. Efird, M. X. Wei, X. O. Breakefield, and E. A. Chiocca. 1994. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54:5745-5751.
12. Boviatsis, E. J., J. M. Scharf, M. Chase, K. Harrington, N. W. Kowall, X. O. Breakefield, and E. A. Chiocca. 1994. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1: 323-331.
13. Candinas, D., B. A. Lesnikoski, W. W. Hancock, I. Otsu, N. Koyamada, A. P. Dalmasso, S. C. Robson, and F. H. Bach. 1996. Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts. Transplantation 62:1-5.
14. Candinas, D., B. A. Lesnikoski, S. C. Robson, T. Miyatake, S. M. Scesney, H. C. Marsh, Jr., U. S. Ryan, A. P. Dalmasso, W. W. Hancock, and F. H. Bach. 1996. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 62:336-342.
15. Chambers, R., G. Y. Gillespie, L. Soroceanu, S. Andreansky, S. Chatterjee, J. Chou, B. Roizman, and R. J. Whitley. 1995. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92: 1411-1415.
16. Chase, M., R. Y. Chung, and E. A. Chiocca. 1998. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16:444-448.
17. Chung, R. Y., Y. Saeki, and E. A. Chiocca. 1999. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73:7556-7564.
18. Cochrane, C. G., H. J. Muller-Eberhard, and B. S. Aikin. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:55-69.
19. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
20. Costa, J., A. S. Rabson, C. Yee, and T. S. Tralka. 1977. Immunoglobulin binding to herpes virus-induced Fc receptors inhibits virus growth. Nature 269:251-252.
21. Cunningham, C., and A. J. Davison. 1993. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 197:116-124.
22. Dubin, G., S. Basu, D. L. Mallory, M. Basu, R. Tal-Singer, and H. M. Friedman. 1994. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J. Virol. 68:2478-2485.
23. Dubin, G., N. O. Fishman, R. J. Eisenberg, G. H. Cohen, and H. M. Friedman. 1992. The role of herpes simplex virus glycoproteins in immune evasion. Curr. Top. Microbiol. Immunol. 179:111-120.
24. Elliott, P. J., N. J. Hayward, M. R. Huff, T. L. Nagle, K. L. Black, and R. T. Bartus. 1996. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp. Neurol. 141:214-224.
25. Emerich, D. F., P. Snodgrass, R. Dean, M. Agostino, B. Hasler, M. Pink, H. Xiong, B. S. Kim, and R. T. Bartus. 1999. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br. J. Cancer. 80:964-970.
26. Ferran, C., D. M. Stroka, A. Z. Badrichani, J. T. Cooper, C. J. Wrighton, M. Soares, S. T. Grey, and F. H. Bach. 1998. A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 91:2249-2258.
27. Friedman, H. M., L. Wang, N. O. Fishman, J. D. Lambris, R. J. Eisenberg, G. H. Cohen, and J. Lubinski. 1996. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J. Virol. 70:4253-4260.
28. Geller, A. I., and A. Freese. 1990. Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. Proc. Natl. Acad. Sci. USA 87:1149-1153.
29. + T-cell response. J. Exp. Med. 187:341-348.
30. Goldstein, D. J., and S. K. Weller. 1988. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41-51.
31. Goldstein, D. J., and S. K. Weller. 1988. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J. Virol. 62:2970-2977.
32. Hofmann, C., and M. Strauss. 1998. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 5:531-536.
33. Huemer, H. P., H. J. Menzel, D. Potratz, B. Brake, D. Falke, G. Utermann, and M. P. Dierich. 1988. Herpes simplex virus binds to human serum lipoprotein. Intervirology 29:68-76.
34. Hunter, W. D., R. L. Martuza, F. Feigenbaum, T. Todo, T. Mineta, T. Yazaki, M. Toda, J. T. Newsome, R. C. Platenberg, H. J. Manz, and S. D. Rabkin. 1999. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73:6319-6326.
35. Ikeda, K., T. Ichikawa, H. Wakimoto, J. Silver, T. Deisboeck, D. Finkelstein, G. I. Harsh, D. Louis, R. Bartus, F. Hochberg, and E. Chiocca. 1999. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5:881-889.
36. Johansson, P. J., and L. Kjellen. 1988. Inhibition of herpes simplex virus growth caused by preparations of animal immunoglobulins is not dependent on Fc-Fc receptor interactions. Intervirology 29:334-338.
37. Kesari, S., B. P. Randazzo, T. Valyi-Nagy, Q. S. Huang, S. M. Brown, A. R. MacLean, V. M. Lee, J. Q. Trojanowski, and N. W. Fraser. 1995. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Investig. 73:636-648.
38. Kirn, D., T. Hermiston, and F. McCormick. 1998. ONYX-015: clinical data are encouraging [letter; comment]. Nat. Med. 4:1341-2.
39. Kodukula, P., T. Liu, N. V. Rooijen, M. J. Jager, and R. L. Hendricks. 1999. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J. Immunol. 162:2895-2905.
40. Kohl, S. 1991. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev. Infect. Dis. 13:108-114.
41. Koyamada, N., T. Miyatake, D. Candinas, P. Hechenleitner, J. Siegel, W. W. Hancock, F. H. Bach, and S. C. Robson. 1996. Apyrase administration prolongs discordant xenograft survival. Transplantation 62:1739-1743.
42. Kramm, C. M., M. Chase, U. Herrlinger, A. Jacobs, P. A. Pechan, N. G. Rainov, M. Sena-Esteves, M. Aghi, F. H. Barnett, E. A. Chiocca, and X. O. Breakefield. 1997. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:2057-2068.
43. Kroll, R. A., and E. A. Neuwelt. 1998. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42: 1083-1100.
44. Kroshus, T. J., S. A. Rollins, A. P. Dalmasso, E. A. Elliott, L. A. Matis, S. P. Squinto, and R. M. Bolman III. 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60:1194-1202.
45. Laquerre, S., D. B. Anderson, D. B. Stolz, and J. C. Glorioso. 1998. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72:9683-9697.
46. Leventhal, J. R., A. P. Dalmasso, J. W. Cromwell, J. L. Platt, C. J. Manivel, R. M. D. Bolman, and A. J. Matas. 1993. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55:857-866.
47. Lorence, R. M., B. B. Katubig, K. W. Reichard, H. M. Reyes, A. Phuangsab, M. D. Sassetti, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54:6017-6021.
48. Lorence, R. M., K. W. Reichard, B. B. Katubig, H. M. Reyes, A. Phuangsab, B. R. Mitchell, C. J. Cascino, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86:1228-1233.
49. Lubinski, J., T. Nagashunmugam, and H. M. Friedman. 1998. Viral interference with antibody and complement. Semin. Cell Dev. Biol. 9:329-337.
50. Lubinski, J. M., L. Wang, A. M. Soulika, R. Burger, R. A. Wetsel, H. Colten, G. H. Cohen, R. J. Eisenberg, J. D. Lambris, and H. M. Friedman. 1998 Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72:8257-8263.
51. Markert, J. M., A. Malick, D. M. Coen, and R. L. Martuza. 1993 Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603.
52. Martuza, R. L., A. Malick, J. M. Markert, K. L. Ruffner, and D. M. Coen. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
53. McNearney, T. A., C. Odell, V. M. Holers, P. G. Spear, and J. P. Atkinson. 1987. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J. Exp. Med. 166:1525-1535.
54. Miyatake, T., N. Koyamada, W. W. Hancock, M. P. Soares, and F. H. Bach. 1998. Survival of accommodated cardiac xenografts upon retransplantation into cyclosporine-treated recipients. Transplantation 65:1563-1569.
55. Nagane, M., F. Coufal, H. Lin, O. Bogler, W. K. Cavenee, and H. J. Huang. 1996. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:5079-5086.
56. Nilaver, G., L. L. Muldoon, R. A. Kroll, M. A. Pagel, X. O. Breakefield, B. L. Davidson, and E. A. Neuwelt. 1995. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA 92:9829-9833.
57. Pyles, R. B., R. E. Warnick, C. L. Chalk, B. E. Szanti, and L. M. Parysek. 1997. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8:533-544.
58. Rainov, N. G., K. U. Dobberstein, V. Heidecke, U. Dorant, M. Chase, C. M. Kramm, E. A. Chiocca, and X. O. Breakefield. 1998. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther. 5:158-162.
59. Rainov, N. G., C. Zimmer, M. Chase, C. M. Kramm, E. A. Chiocca, R. Weissleder, and X. O. Breakefield. 1995. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum. Gene Ther. 6:1543-1552.
60. Ram, Z., K. W. Culver, E. M. Oshiro, J. J. Viola, H. L. DeVroom, E. Otto, Z. Long, Y. Chiang, G. J. McGarrity, L. M. Muul, D. Katz, R. M. Blaese, and E. H. Oldfield. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1354-1361.
61. Roth, J. A., S. G. Swisher, J. A. Merritt, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, A. K. El-Naggar, F. V. Fossella, B., S. Glisson, W. K. Hong, F. R. Khurl, J. M. Kurie, J. C. Nesbitt, K. Pisters, J. B. Putnam, D. S. Schrump, D. M. Shin, and G. L. Walsh. 1998. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 25:33-37.
62. Saeki, Y., T. Ichikawa, A. Saeki, E. A. Chiocca, K. Tobler, M. Ackermann, X. O. Breakefield, and C. Fraefel. 1998. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 9:2787-2794.
63. Silbergeld, D. L., R. C. Rostomily, and E. C. Alvord, Jr. 1991. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J. Neurooncol. 10:179-185.
64. Smiley, M. L., and H. M. Friedman. 1985. Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J. Virol. 55:857-861.
65. Soares, M. P., Y. Lin, J. Anrather, E. Csizmadia, K. Takigami, K. Sato, S. T. Grey, R. B. Colvin, A. M. Choi, K. D. Poss, and F. H. Bach. 1998 Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat. Med. 4: 1073-1077.
66. Soares, M. P., A. Muniappan, E. Kaczmarek, K. Koziak, C. J. Wrighton, F. Steinhauslin, C. Ferran, H. Winkler, F. H. Bach, and J. Anrather. 1998. Adenovirus-mediated expression of a dominant negative mutant of p65/ RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. J. Immunol. 161:4572-4582.
67. Srinivas, R. V., B. Birkedal, R. J. Owens, G. M. Anantharamaiah, J. P. Segrest, and R. W. Compans. 1990. Antiviral effects of apolipoprotein A-1 and its synthetic amphipathic peptide analogs. Virology 176:48-57.
68. Srinivas, R. V., Y. V. Venkatachalapathi, Z. Rui, R. J. Owens, K. B. Gupta, S. K. Srinivas, G. M. Anantharamaiah, J. P. Segrest, and R. W. Compans. 1991. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J. Cell Biochem. 45:224-237.
69. Suh, C. H., M. K. Oaks, N. N. Dong, J. G. Pellegrini, D. C. Kress, and A. J. Tector. 1997. Preoperative depletion of C3 improves the survival of guinea pig-to-rat cardiac xenograft recipients. J. Investig. Surg. 10:37-40.
70. Thormar, H., C. E. Isaacs, H. R. Brown, M. R. Barshatzky, and T. Pessolano. 1987. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob. Agents Chemother. 31:27-31.
71. Toda, M., S. D. Rabkin, H. Kojima, and R. L. Martuza. 1999. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10:385-393.
72. Wallner, K. E., J. H. Galicich, G. Krol, E. Arbit, and M. G. Malkin. 1989. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 16:1405-1409.
73. Welsh, R. M., C. L. O'Donnell, D. J. Reed, and R. P. Rother. 1998. Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J. Virol. 72:4650-4656.
74. Yoon, S., E. A. Chiocca, and K. Tanabe. 2000. Treatment of multiple liver metastases hy intravascular delivery of an oncolytic HSV. FASEB J. 14:301-311.